This product is a finalist in the category Home & Professional Devices & Tools of Cosmoprof 2026
Product Description (Function, Benefits, and Target Consumer)
TDX20 XGEN® is a turbine reactor that professionals can use before aesthetic treatments, to allow for the real-time encapsulation of active ingredients, which sees the immediate, controlled loading of active ingredients into genosomes. These ultra-flexible genosomes can cross the skin’s intercellular pathways, enhancing the bioavailability of peptides, antioxidants, and growth factors while protecting the ingredients from oxidation and degradation. Used to encapsulate actives before treatments with Mesolux, Sisneo’s transdermal electroporation system, the encapsulation technology amplifies ingredients’ transdermal transport, accelerating their results. The reactor is used in conjunction with Sisneo’s various kits – Age Solution 360°, Mesolift, and Skin Radiance – allowing professionals to tailor the treatment to different skin concerns while using a single device. The precise reorganization of lipid bilayers that the turbine reactor creates means the genosomes achieve payload efficiency of up to 85%, so that each electroporation treatment is delivered with freshly activated actives at peak potency.
Launch Date (First worldwide launch must have been launched within 12 months prior to the event). Date (Month/Day/Year)
The worldwide launch of TDX20 XGEN® is scheduled to take place at Cosmoprof Worldwide Bologna 2026. The device will be officially introduced to the international market during the exhibition
Retail Price & Fill Sizes
Retail Price: 9.000 €
Fill Sizes: 28x21x21 cm
Product Innovation
TDX20 XGEN introduces the first real-time encapsulation technology for aesthetic treatments. Unlike preloaded liposomes or exosomes, Genosomes open, load, and reseal active ingredients during activation. The XGEN Reactor combines controlled mechanical agitation and ultrasonic sonication to reorganize lipid bilayers, achieving over 85% active encapsulation, a concentration unattainable in conventional laboratories without compromising stability.
This breakthrough redefines transdermal delivery, enabling unprecedented potency, personalization, and clinical performance. No other device offers precise, on-demand encapsulation with such adaptable, high-efficiency vesicles.
Product Claims & Benefits
TDX20 XGEN delivers a new standard of efficacy in non-invasive aesthetic treatments by enabling up to 20 times higher penetration of active ingredients. Its ultraflexible Genosomes traverse intercellular pathways with exceptional efficiency, enhancing the bioavailability of peptides, antioxidants, and growth factors while protecting them from oxidation and degradation. This controlled encapsulation ensures gradual release, sustained performance, and improved safety by reducing off-target exposure. Clinically, the device supports visible improvements in firmness, radiance, and overall skin quality.
For professionals, TDX20 XGEN offers real-time in situ encapsulation, guaranteeing maximum freshness and potency at every session. Its precision dosing allows full personalization according to patient needs, while its technology eliminates formulation instability such as crystallization or phase separation. The system integrates seamlessly with Mesolux electroporation, amplifying transdermal transport and accelerating results. As a modular platform, it works with three targeted kits—Age Solution 360°, Mesolift, and Skin Radiance—allowing clinics to address multiple concerns with a single device. Finally, its in & out protocol ensures continuity between in-clinic treatments and at-home maintenance through the TDX20 Longevity Elixir, reinforcing long-term results.
Research, Clinical Tests & Trials Results (Safety & Dermatological)
Sisneo Bioscience conducted an internal observational study to evaluate the clinical performance of the TDX20 system and TDX20 XGEN device under real-world conditions. Five adult participants presenting visible signs of skin aging — including uneven tone, hyperpigmentation, loss of firmness, and expression lines — received a complete TDX20 treatment protocol. Each subject underwent a single in-clinic session using freshly activated Genosomes, followed by a four-week home protocol with the TDX20 Longevity Elixir.
The in-clinic phase was performed using Mesolux, Sisneo’s precision transdermal electroporation system. The TDX20 Genosome Complex (Phase A) was combined with a selected ultra-concentrated active (Phase B) and activated in the XGEN Reactor, enabling homogenization, in situ encapsulation and stabilization. Internal laboratory measurements demonstrated encapsulation efficiencies exceeding 85%, allowing active concentrations difficult to achieve through conventional formulation without compromising stability. The activated formula was then delivered through electroporation, temporarily increasing tissue permeability and enhancing penetration depth and bioavailability of encapsulated actives.
Standardized photographs were taken at baseline, immediately post-treatment, two weeks, and four weeks after treatment. Visible improvements were observed immediately after the procedure, with progressive enhancement over time, indicating both rapid clinical response and sustained efficacy.
Consistent improvements were observed across multiple parameters. Skin tone appeared more even, with reduced hyperpigmentation and dark spots. Participants showed increased luminosity and radiance, alongside smoother texture and improved hydration. Fine lines and expression wrinkles appeared softened, while deeper folds showed reduced visual prominence, suggesting improved dermal support. Participants also reported subjective improvements, describing their skin as firmer, more elastic, and visibly rejuvenated. The combination of real-time encapsulation, electroporation-enhanced delivery, and continued home application contributed to results that were both immediate and maintained throughout the follow-up period.
These findings align with established dermatological research supporting deformable vesicular delivery systems and electroporation-based transdermal enhancement. Foundational studies by Cevc & Blume (1992–2001) demonstrated that elastic lipid nanocarriers can cross the stratum corneum more effectively than conventional liposomes. The 500 Dalton Rule (Bos & Meinardi, 2000) further confirms the need for enabling technologies to facilitate penetration of most active molecules. More recent research, including Bellefroid et al. (2019) and Zorec et al. (2018), highlights how deformable nanocarriers combined with electroporation significantly enhance penetration, stability, and bioavailability, supporting the scientific rationale behind the XGEN Reactor and Mesolux technologies.
Certifications, Patents & Regulatory Compliance
TDX20 XGEN is manufactured under two internationally recognized quality standards that ensure maximum safety, reliability, and traceability. Sisneo Bioscience operates under ISO 13485, the global benchmark for the development and manufacturing of medical devices. This certification guarantees strict control over every stage of production, from risk management and documentation to testing, verification, and post market surveillance. It ensures that each device meets the highest requirements for performance, safety, and regulatory compliance in clinical environments.
In parallel, Sisneo holds ISO 22716 certification for Good Manufacturing Practices in cosmetics. This standard ensures excellence in the handling, formulation, and quality control of all cosmetic components involved in the TDX20 system, including the Genosome Complex and the ultra concentrated active phases. It establishes rigorous procedures for hygiene, traceability, raw material management, and batch consistency.
Both certifications are supported by Sisneo’s fully integrated production line in Valencia, Spain, where concept development, engineering, assembly, and final verification take place under one roof. This end to end control strengthens regulatory compliance across global markets and ensures that every TDX20 XGEN® device is built with precision, durability, and uncompromising quality.
Ingredients List & Formulation (Mandatory, if not specified disqualification from the contest)
DEVICES N/A
Technology Features
TDX20 XGEN® Turbine Reactor is the first professional real time encapsulation that enables immediate, controlled loading of active ingredients into Genosomes. Its mechanical stress program integrates multidirectional agitation and ultrasonic sonication, guiding the formula through a three stage sequence of homogenization, Genosome activation and final stabilization. This precise reorganization of lipid bilayers allows Genosomes to achieve exceptional payload efficiency up to 85%, ensuring that each treatment is delivered with freshly activated actives at peak potency.
The platform is compatible with three ultra concentrated active kits, allowing professionals to tailor protocols to specific skin concerns with a single device. Its architecture supports a wide spectrum of molecules (including hydrophilic and lipophilic actives, peptides, proteins and future advanced payloads such as nucleic acids) positioning XGEN as a forward ready system for next generation cosmetic biotechnology.
Engineered for precision and reproducibility, TDX20 XGEN delivers consistent activation cycles that maintain structural integrity and encapsulation efficiency. Its modular design integrates seamlessly into professional environments, establishing a new standard for real time formulation and advanced delivery systems within the skincare industry.
Sustainability List of Certifications
Sisneo Bioscience integrates sustainability into the entire lifecycle of the TDX20 XGEN through responsible engineering, manufacturing, and environmental commitment. The device is designed to be energy efficient, minimizing waste during operation and reducing the environmental impact of professional aesthetic treatments. Thanks to a fully consolidated, in house manufacturing model, Sisneo significantly lowers its carbon footprint by eliminating external transport between production phases and optimizing resource use.
All development, production, and assembly take place in our facilities in Valencia, Spain, where we maintain complete control over materials, processes, and environmental standards. This integrated approach ensures that every component (from microprocessor software and electronic systems to enclosures, applicators, and accessories) is conceived with durability, precision, and sustainability in mind.
Beyond manufacturing, Sisneo actively contributes to environmental restoration through its participation in reforestation programs in collaboration with plantaunbosque.org. This initiative reinforces a long term commitment to ecological regeneration and responsible innovation.
Our end to end production model not only enhances product reliability but also supports a more sustainable industry by reducing waste, improving energy efficiency, and ensuring transparent, traceable, and environmentally conscious manufacturing practices.
How to use it
The protocol begins by dispensing the TDX20 Genosome Complex (Phase A) into the vial containing the selected ultra concentrated active (Phase B) using the precision pipette included in the kit. Once combined, the vial is placed inside the XGEN Reactor, which performs a three step cycle of homogenization, Genosome activation and stabilization to generate a freshly activated concentrate. Half of this formula is applied during the in clinic session using Mesolux® electroporation for enhanced penetration. The remaining half is added to the TDX20 Longevity Elixir to prepare the personalized four week home treatment.
Market Positioning & Distribution Markets
TDX20 XGEN is positioned as a premium, next-generation professional device developed for advanced aesthetic clinics seeking the highest level of performance, precision, and scientific differentiation. Its real-time encapsulation technology, capable of achieving significantly enhanced active ingredient penetration, places it in a category of its own within professional skincare. By combining in situ encapsulation with personalized treatment activation, TDX20 XGEN introduces a new level of potency, adaptability, and clinical performance, establishing a new benchmark for results-driven aesthetic practices.
Sisneo Bioscience has introduced the TDX20 system through exclusive presentations to selected clients in the United Kingdom, Hungary, Cyprus, Greece, and the Dominican Republic. This controlled introduction has allowed the company to validate clinical performance, gather professional feedback, and ensure alignment with clinics that prioritize scientific rigor and premium treatment standards.
With the official launch of TDX20 XGEN, Sisneo Bioscience aims to expand internationally through carefully selected partners, with a strategic focus on Europe and the Middle East, where demand for high-performance, non-invasive aesthetic technologies continues to grow. The company’s objective is to collaborate with partners who value innovation, exclusivity, and long-term technological differentiation.
Website and/or Social Media Channels + Editorial pitch
Website: www.sisneobioscience.com
Instagram: @sisneobioscience
LinkedIn: Sisneo Bioscience
Editorial Pitch: The first device to encapsulate actives instantly, delivering 20 times higher penetration and elevating non invasive professional treatments to unprecedented performance.
